Search

ADMA Biologics Inc

Open

SectorHealthcare

9.47 0.64

Overview

Share price change

24h

Current

Min

9.23

Max

9.52

Key metrics

By Trading Economics

Income

-7.5M

38M

Sales

9.9M

124M

P/E

Sector Avg

13.929

57.002

EPS

0.16

Profit margin

30.405

Employees

640

EBITDA

-3.8M

57M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+80.66% upside

Dividends

By Acuity

Next Earnings

4 lis 2026

Market Stats

By TradingEconomics

Market Cap

158M

2.2B

Previous open

8.83

Previous close

9.47

News Sentiment

By Acuity

100%

0%

325 / 340 Ranking in Healthcare

ADMA Biologics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 sie 2026, 20:02 UTC

Social Media

ADMA Biologics shares are lower amid concerns over financial practices and potential SEC scrutiny, despite claims of an internal review clearing the company.

12 sie 2026, 19:46 UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

11 sie 2026, 22:56 UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

7 sie 2026, 19:46 UTC

Correlated Moves
News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

6 sie 2026, 20:02 UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

5 sie 2026, 23:02 UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

4 sie 2026, 19:46 UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

3 sie 2026, 19:16 UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

31 lip 2026, 20:06 UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

30 lip 2026, 19:39 UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

29 lip 2026, 18:17 UTC

News
Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

28 lip 2026, 20:06 UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

27 lip 2026, 19:41 UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

24 lip 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22 lip 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21 lip 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20 lip 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Price Target

By TipRanks

80.66% upside

12 Months Forecast

Average 17 USD  80.66%

High 21 USD

Low 12 USD

Based on 4 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Sentiment

By Acuity

325 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
help-icon Live chat